Ibogaine research advances as Trump signs executive order

President Trump signed an executive order to ease federal restrictions on the psychedelic ibogaine and announced $50 million in federal research funding. The FDA said it will begin steps to allow human trials and add three psychedelics to a priority review pilot program.

President Trump signed an executive order intended to ease federal restrictions on the psychedelic substance ibogaine and to encourage more U.S. research. He announced a $50 million federal research investment and referenced a pathway under the FDA’s Right To Try rule for some patients. Health officials present included HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary, and podcaster Joe Rogan attended the announcement. The action comes amid limited clinical evidence and growing public interest in ibogaine for conditions such as PTSD and addiction. What officials said: - President Trump signed an executive order to ease restrictions on ibogaine and announced a $50 million federal investment for research. - The administration referenced using the FDA’s Right To Try pathway for some patients, and the FDA said it will begin processes to permit human trials and add three psychedelics to the National Priority Voucher pilot program. - Ibogaine is currently a Schedule I substance under the DEA; available clinical evidence is limited, and studies have reported heart-related risks, including deaths after use. Summary: The executive order indicates a federal shift toward supporting research into ibogaine, including a pledged $50 million and possible patient access under Right To Try. The FDA will start procedures to allow human trials and add certain psychedelics to a priority review pilot; specific details of implementation remain undetermined.